You are here
This report was prepared in accordance with the requirements of the National Health Reform Act 2011 and section 46 of the Public Governance, Performance and Accountability Act 2013. The report includes IHPA's audited Financial Statements, as required by section 42 of the Public Governance, Performance and Accountability Act.
Chimeric antigen receptor T cell therapy (CAR-T cell): guidelines for costing, counting and reconciliation of funding18 June 2020
The guidelines set out the scope, funding, costing, counting and reconciliation of funding for the chimeric antigen receptor T cell therapy (CAR-T cell) immunotherapy program using the Novartis CAR-T product Kymriah. The CAR-T program is for paediatric and young adults (up to 25 years) with Acute Lymphoblastic Leukaemia (ALL) who relapse or do not respond to initial therapy.
This guide is intended to provide assistance when assigning care types, especially for those patients that may potentially have care that applies to more than one care type.
This report is prepared in accordance with the Requirements for Annual Reports, as issued by the Department of the Prime Minister and Cabinet and approved by the Joint Committee of Public Accountants Audit under sub sections 63(2) and 70(2) of the Public Service Act 1999. The report is a formal accountability document that details the activities of the Independent Hospital Pricing Authority (IHPA) from 1 July 2014 – 30 June 2015.
IHPA has developed a robust set of standard costs for the revised List of standard items associated with conducting clinical trials in Australia.